Peptide neurotransmitters and their implications for the treatment of tardive dyskinesia.
D000818:Animals; D001921:Brain / Q000503:physiopathology; D002766:Cholecystokinin / Q000627:therapeutic use; D004151:Dipeptides / Q000627:therapeutic use; D004298:Dopamine / Q000378:metabolism; D004409:Dyskinesia, Drug-Induced / Q000188:drug therapy* / Q000503:physiopathology; D004723:Endorphins / Q000502:physiology / Q000627:therapeutic use; D005260:Female; D006801:Humans; D009020:Morphine / Q000627:therapeutic use; D009270:Naloxone / Q000627:therapeutic use; D009479:Neuropeptides; D009496:Neurotensin / Q000627:therapeutic use; D018377:Neurotransmitter Agents / Q000627:therapeutic use*; D010455:Peptides / Q000627:therapeutic use*; D010456:Peptides, Cyclic; D051381:Rats; D013373:Substance P / Q000627:therapeutic use
D004151:Dipeptides; D004723:Endorphins; D009479:Neuropeptides; D018377:Neurotransmitter Agents; D010455:Peptides; D010456:Peptides, Cyclic; D013373:Substance P; D009270:Naloxone; D009496:Neurotensin; C021166:cyclo(leucylglycine); D009020:Morphine; D002766:Cholecystokinin; D004298:Dopamine